BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 35484633)

  • 21. Acquired On-Target Clinical Resistance Validates FGFR4 as a Driver of Hepatocellular Carcinoma.
    Hatlen MA; Schmidt-Kittler O; Sherwin CA; Rozsahegyi E; Rubin N; Sheets MP; Kim JL; Miduturu C; Bifulco N; Brooijmans N; Shi H; Guzi T; Boral A; Lengauer C; Dorsch M; Kim RD; Kang YK; Wolf BB; Hoeflich KP
    Cancer Discov; 2019 Dec; 9(12):1686-1695. PubMed ID: 31575540
    [TBL] [Abstract][Full Text] [Related]  

  • 22. FGF19-mediated ELF4 overexpression promotes colorectal cancer metastasis through transactivating FGFR4 and SRC.
    Chen X; Chen J; Feng W; Huang W; Wang G; Sun M; Luo X; Wang Y; Nie Y; Fan D; Wu K; Xia L
    Theranostics; 2023; 13(4):1401-1418. PubMed ID: 36923538
    [No Abstract]   [Full Text] [Related]  

  • 23. Fibroblast growth factor receptor 4 regulates tumor invasion by coupling fibroblast growth factor signaling to extracellular matrix degradation.
    Sugiyama N; Varjosalo M; Meller P; Lohi J; Hyytiäinen M; Kilpinen S; Kallioniemi O; Ingvarsen S; Engelholm LH; Taipale J; Alitalo K; Keski-Oja J; Lehti K
    Cancer Res; 2010 Oct; 70(20):7851-61. PubMed ID: 20876804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models.
    French DM; Lin BC; Wang M; Adams C; Shek T; Hötzel K; Bolon B; Ferrando R; Blackmore C; Schroeder K; Rodriguez LA; Hristopoulos M; Venook R; Ashkenazi A; Desnoyers LR
    PLoS One; 2012; 7(5):e36713. PubMed ID: 22615798
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interrupting the FGF19-FGFR4 Axis to Therapeutically Disrupt Cancer Progression.
    Lang L; Shull AY; Teng Y
    Curr Cancer Drug Targets; 2019; 19(1):17-25. PubMed ID: 29557750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. FGFR4 and EZH2 inhibitors synergistically induce hepatocellular carcinoma apoptosis via repressing YAP signaling.
    Yang Y; Zhang Y; Cao J; Su Z; Li F; Zhang P; Zhang B; Liu R; Zhang L; Xie J; Li J; Zhang J; Chen X; Hong A
    J Exp Clin Cancer Res; 2023 Apr; 42(1):96. PubMed ID: 37085881
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MOB2 suppresses GBM cell migration and invasion via regulation of FAK/Akt and cAMP/PKA signaling.
    Jiang K; Yao G; Hu L; Yan Y; Liu J; Shi J; Chang Y; Zhang Y; Liang D; Shen D; Zhang G; Meng S; Piao H
    Cell Death Dis; 2020 Apr; 11(4):230. PubMed ID: 32286266
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype.
    Li H; Martin A; David V; Quarles LD
    Am J Physiol Endocrinol Metab; 2011 Mar; 300(3):E508-17. PubMed ID: 21139072
    [TBL] [Abstract][Full Text] [Related]  

  • 29. FGF19/FGFR4-mediated elevation of ETV4 facilitates hepatocellular carcinoma metastasis by upregulating PD-L1 and CCL2.
    Xie M; Lin Z; Ji X; Luo X; Zhang Z; Sun M; Chen X; Zhang B; Liang H; Liu D; Feng Y; Wang Y; Li Y; Liu B; Huang W; Xia L
    J Hepatol; 2023 Jul; 79(1):109-125. PubMed ID: 36907560
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF19/FGFR4 signaling axis confines and switches the role of melatonin in head and neck cancer metastasis.
    Lang L; Xiong Y; Prieto-Dominguez N; Loveless R; Jensen C; Shay C; Teng Y
    J Exp Clin Cancer Res; 2021 Mar; 40(1):93. PubMed ID: 33691750
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fibroblast growth factor 19 expression correlates with tumor progression and poorer prognosis of hepatocellular carcinoma.
    Miura S; Mitsuhashi N; Shimizu H; Kimura F; Yoshidome H; Otsuka M; Kato A; Shida T; Okamura D; Miyazaki M
    BMC Cancer; 2012 Feb; 12():56. PubMed ID: 22309595
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma.
    Liang Y; Bollen AW; Aldape KD; Gupta N
    BMC Cancer; 2006 Apr; 6():97. PubMed ID: 16623952
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Inhibition of fibroblast growth factor 19 reduces tumor growth by modulating beta-catenin signaling.
    Pai R; Dunlap D; Qing J; Mohtashemi I; Hotzel K; French DM
    Cancer Res; 2008 Jul; 68(13):5086-95. PubMed ID: 18593907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. FGFR4 role in epithelial-mesenchymal transition and its therapeutic value in colorectal cancer.
    Peláez-García A; Barderas R; Torres S; Hernández-Varas P; Teixidó J; Bonilla F; de Herreros AG; Casal JI
    PLoS One; 2013; 8(5):e63695. PubMed ID: 23696849
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
    Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
    J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of glycosyltransferase PomGnT1 in glioblastoma progression.
    Lan J; Guo P; Lin Y; Mao Q; Guo L; Ge J; Li X; Jiang J; Lin X; Qiu Y
    Neuro Oncol; 2015 Feb; 17(2):211-22. PubMed ID: 25085363
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGF-1/-3/FGFR4 signaling in cancer-associated fibroblasts promotes tumor progression in colon cancer through Erk and MMP-7.
    Bai YP; Shang K; Chen H; Ding F; Wang Z; Liang C; Xu Y; Sun MH; Li YY
    Cancer Sci; 2015 Oct; 106(10):1278-87. PubMed ID: 26183471
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fibroblast growth factor receptor 4 promotes progression and correlates to poor prognosis in cholangiocarcinoma.
    Xu YF; Yang XQ; Lu XF; Guo S; Liu Y; Iqbal M; Ning SL; Yang H; Suo N; Chen YX
    Biochem Biophys Res Commun; 2014 Mar; 446(1):54-60. PubMed ID: 24565842
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FGFR1 and FGFR4 oncogenicity depends on n-cadherin and their co-expression may predict FGFR-targeted therapy efficacy.
    Quintanal-Villalonga Á; Ferrer I; Guruceaga E; Cirauqui C; Marrugal Á; Ojeda L; García S; Zugazagoitia J; Muñoz-Galván S; Lopez-Rios F; Montuenga L; Vicent S; Molina-Pinelo S; Carnero A; Paz-Ares L
    EBioMedicine; 2020 Mar; 53():102683. PubMed ID: 32114392
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Small-molecule inhibitors of FGFR, integrins and FAK selectively decrease L1CAM-stimulated glioblastoma cell motility and proliferation.
    Anderson HJ; Galileo DS
    Cell Oncol (Dordr); 2016 Jun; 39(3):229-42. PubMed ID: 26883759
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.